Wall Street’s appetite for risk lit up again Thursday as Drugs Made In America Acquisition II stormed onto the Nasdaq, raising a staggering $500 million in its debut. The special purpose acquisition company, or SPAC, priced 50 million units at $10 each, instantly becoming the largest SPAC listing of 2025.

Trading under the ticker DMIIU, the deal isn’t just another Wall Street experiment—it’s a thunderclap that recalls the high-flying SPAC craze of just a few years ago. The offering is set to close Friday, with underwriters holding a 45-day option to buy 7.5 million more units if demand keeps surging.

Targeting the Pharma Frontier

Though SPACs are blank-check vehicles with broad horizons, this one carries a sharpened focus: companies in the pharmaceutical sector. The filing with the U.S. Securities and Exchange Commission leaves room for flexibility across industries and geographies, but the mission is clear—hunt down pharma players and take them public.

This is the second vehicle under the Drugs Made In America banner to hit the market this year. Its predecessor, which raised $200 million in January, remains in search of a target. Both are run by the same veteran management team, giving investors a sense of continuity and strategic focus.

Meet the Team Behind the Wheel

At the helm sits Lynn Stockwell, CEO and executive chair, who also leads the first iteration of the SPAC. Stockwell isn’t new to the pharmaceutical frontier—she founded Bright Green Corp., a cannabis-focused drugmaker where she still serves as CEO.

Alongside her, Glenn Worman reprises his role as CFO, juggling the same position at the first Drugs Made In America SPAC. Worman also brings financial firepower from his role as partner at SeatonHill Partners LP’s New York office.

Market Ripples and Legal Muscle

Every unit sold in the IPO includes one share of common stock plus one-tenth of a share right upon merger completion, giving investors a slice of the future acquisition.

The IPO, at $500 million, isn’t just the year’s biggest—it’s the largest SPAC debut since Gores Holdings IX Inc. raised $525 million in February 2022, according to Renaissance Capital. That statistic underscores how rare such massive listings have become in a tighter post-SPAC-boom market.

On the legal front, Loeb & Loeb LLP guided the SPAC with a team led by Mitchell Nussbaum and G. Alex Weniger-Araujo. Meanwhile, the underwriters leaned on Ellenoff Grossman & Schole LLP, with Douglas Ellenoff, Stuart Neuhauser, and Anthony Ain steering their side of the deal.

A High-Stakes Gamble

SPACs have been compared to financial time bombs—silent until they strike with a merger that can either ignite fortunes or leave investors in ashes. For Drugs Made In America Acquisition II, the journey has just begun. With half a billion dollars in hand, Wall Street now waits to see what kind of pharmaceutical titan this blank-check juggernaut will deliver.